BioSpace News Archive

STRATA Skin Sciences, Inc. announced that, as previously reported on its Form 8-K filed on October 30, 2023, effective as of the close of trading on October 31, 2023, the Company granted equity-based awards, in accordance with Nasdaq Listing Rule 5635, to Dr. Dolev Rafaeli as an inducement material to Dr. Rafaeli entering into an employment agreement with the Company and commencing employment as its Vice-Chairman, Chief Executive Officer and President.

Lexicon Pharmaceuticals, Inc. announced that Matthew Cullen is joining the company as vice president of value and access, effective November 1, 2023, and Lisa DeFrancesco will join as head of investor relations and corporate strategy, effective November 13, 2023.

Invivyd, Inc., a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, announced that it will present at the following investor conferences.

AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the Jefferies London Healthcare Conference on Tuesday, November 14, 2023, at 4:30 p.m. Greenwich Mean Time (8:30 a.m. Pacific Time).

Human Immunology Biosciences (HI-Bio™), a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases (IMDs), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for felzartamab in primary membranous nephropathy (PMN).

Plus Therapeutics, Inc. announced that its Board of Directors has approved a share repurchase program, with authorization to repurchase up to $500,000 of the Company’s outstanding common stock.

Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for the phase 2 study for Radspherin® in patients with peritoneal carcinomatosis from ovarian cancer.

Mirion announced that Chief Executive Officer, Thomas Logan, and Chief Financial Officer, Brian Schopfer, will present at the Baird Global Industrial Conference in Chicago, IL. The presentation will begin at 10:40 AM ET on Tuesday, November 7, 2023.

EpimAb Biotherapeutics is excited to announce that the company will present the first-in-human results for EMB-06 in a late-breaking poster presentation at the 2023 Society for Immunotherapy of Cancer Annual Meeting to be held in San Diego, California, from November 3-5.

Novavax, Inc. (Nasdaq: NVAX) today announced that the Nuvaxovid™ XBB.1.5 dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2601) has been recommended for approval for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals aged 12 and older in the European Union by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency.